Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

In the context of the ongoing debate about an innovation crisis in the pharmaceutical industry, we study the success …

different configurations of the patent system upon innovation and competition. The model is able to replicate the main stylized … adverse effects in terms of innovation outcomes, as well as of market competition and consumer welfare. Such general …

facilitate follow-on innovation and benefit latecomer firms, especially in the pharmaceutical industry. In this paper, we provide … between firms' innovation and imitation strategies for the design of innovation policies …

I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003–2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger …

While most economists believe that public scientific research fuels industry innovation and economic growth, systematic … size as a significant driver of drug innovation in the pharmaceutical industry, but they did not find any evidence … supporting science-driven innovation from publicly funded research. This paper uses new data on biomedical research investments …